Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

被引：36
作者：
Mendes, Rodrigo E. [1 ]
Flamm, Robert K. [1 ]
Hogan, Patricia A. [2 ]
Ross, James E. [1 ]
Jones, Ronald N. [1 ,3 ]
机构：
[1] JMI Labs, North Liberty, IA USA
[2] Pfizer Inc, Collegeville, PA USA
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 02期
关键词：
STAPHYLOCOCCUS-AUREUS; SPECTRUM ANALYSIS; RIBOSOMAL-RNA; VANCOMYCIN; BACTEREMIA; STRAIN; GENE;
D O I：
10.1128/AAC.02112-13
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
This study summarizes the linezolid susceptibility testing results for 7,429 Gram-positive pathogens from 60 U.S. sites collected during the 2012 sampling year for the LEADER Program. Linezolid showed potent activity when tested against 2,980 Staphylococcus aureus isolates, inhibiting all but 3 at <= 2 mu g/ml. Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000.
引用
收藏
页码：1243 / 1247
页数：5
相关论文
共 22 条
[1]  
Clinical and Laboratory Standards Institute, 2012, M07A9 CLIN LAB STAND
[2]  
Clinical and Laboratory Standards Institute, 2013, M100S23 CLIN LAB STA
[3]   LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States [J].
Farrell, David J. ;
Mendes, Rodrigo E. ;
Ross, James E. ;
Sader, Helio S. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (08) :3684-3690
[4]   Linezolid surveillance program results for 2008 (LEADER Program for 2008) [J].
Farrell, David J. ;
Mendes, Rodrigo E. ;
Ross, James E. ;
Jones, Ronald N. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 65 (04) :392-403
[5]   Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 [J].
Flamm, Robert K. ;
Mendes, Rodrigo E. ;
Ross, James E. ;
Sader, Helio S. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (02) :1077-1081
[6]   LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers) [J].
Flamm, Robert K. ;
Farrell, David J. ;
Mendes, Rodrigo E. ;
Ross, James E. ;
Sader, Helio S. ;
Jones, Ronald N. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2012, 74 (01) :54-61
[7]   Nosocomial spread of linezolid-resistant, vancomycin-resistant enterococcus faecium [J].
Herrero, IA ;
Issa, NC ;
Patel, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (11) :867-869
[8]   LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers) [J].
Jones, Ronald N. ;
Fritsche, Thomas R. ;
Sader, Helio S. ;
Ross, James E. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 59 (03) :309-317
[9]   United States resistance surveillance results for linezolid (LEADER Program for 2007) [J].
Jones, Ronald N. ;
Ross, James E. ;
Castanheira, Mariana ;
Mendes, Rodrigo E. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 62 (04) :416-426
[10]   Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA [J].
Meka, VG ;
Pillai, SK ;
Sakoulas, G ;
Wennersten, C ;
Venkataraman, L ;
DeGirolami, PC ;
Eliopoulos, GM ;
Moellering, RC ;
Gold, HS .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (02) :311-317
123